Neoadjuvant therapy in breast cancer

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Neoadjuvant therapy (NAT), often referred to as primary therapy, is a wellestablished approach in the treatment of early breast cancer [1, 2]. Historically, NAT was initially used in women with locally advanced breast cancer. In this setting it represented the only chance for a patient with an otherwise inoperable cancer of the breast to obtain a tumor regression that made surgery feasible. These experiences in locally advanced tumors suggested that the primary breast cancers regressed frequently and, sometimes, became clinically undetectable during NAT. From locally advanced tumors, NAT was then studied in women with operable breast cancers, in whom it was speculated that anticancer treatment administered before surgery would offer a number of advantages compared to the traditional approach of surgery followed by adjuvant treatments. For example, in animal models, removal of the primary tumor was shown to have a permissive effect on distant micrometastases [3]; consequently, in the interval after breast surgery, micrometastases could grow to the extent that subsequent adjuvant treatments lost their efficacy. When potent chemotherapy agents such as the anthracyclines and, later, the taxanes became available, the rates of tumor regression observed in breast tumors were so impressive that NAT became synonymous with neoadjuvant chemotherapy (NAC).

Original languageEnglish
Title of host publicationImaging Tumor Response to Therapy
PublisherSpringer-Verlag Italia s.r.l.
Pages95-108
Number of pages14
ISBN (Print)9788847026131, 9788847026124
DOIs
Publication statusPublished - Jan 1 2012

Fingerprint

Neoadjuvant Therapy
Tumors
Breast Neoplasms
Surgery
Neoplasm Micrometastasis
Chemotherapy
Neoplasms
Therapeutics
Drug Therapy
Taxoids
Anthracyclines
Animals
Breast
Animal Models

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Martincich, L., Bertotto, I., & Montemurro, F. (2012). Neoadjuvant therapy in breast cancer. In Imaging Tumor Response to Therapy (pp. 95-108). Springer-Verlag Italia s.r.l.. https://doi.org/10.1007/978-88-470-2613-1_6

Neoadjuvant therapy in breast cancer. / Martincich, Laura; Bertotto, Ilaria; Montemurro, Filippo.

Imaging Tumor Response to Therapy. Springer-Verlag Italia s.r.l., 2012. p. 95-108.

Research output: Chapter in Book/Report/Conference proceedingChapter

Martincich, L, Bertotto, I & Montemurro, F 2012, Neoadjuvant therapy in breast cancer. in Imaging Tumor Response to Therapy. Springer-Verlag Italia s.r.l., pp. 95-108. https://doi.org/10.1007/978-88-470-2613-1_6
Martincich L, Bertotto I, Montemurro F. Neoadjuvant therapy in breast cancer. In Imaging Tumor Response to Therapy. Springer-Verlag Italia s.r.l. 2012. p. 95-108 https://doi.org/10.1007/978-88-470-2613-1_6
Martincich, Laura ; Bertotto, Ilaria ; Montemurro, Filippo. / Neoadjuvant therapy in breast cancer. Imaging Tumor Response to Therapy. Springer-Verlag Italia s.r.l., 2012. pp. 95-108
@inbook{47d995e296514940864bd35ea044032c,
title = "Neoadjuvant therapy in breast cancer",
abstract = "Neoadjuvant therapy (NAT), often referred to as primary therapy, is a wellestablished approach in the treatment of early breast cancer [1, 2]. Historically, NAT was initially used in women with locally advanced breast cancer. In this setting it represented the only chance for a patient with an otherwise inoperable cancer of the breast to obtain a tumor regression that made surgery feasible. These experiences in locally advanced tumors suggested that the primary breast cancers regressed frequently and, sometimes, became clinically undetectable during NAT. From locally advanced tumors, NAT was then studied in women with operable breast cancers, in whom it was speculated that anticancer treatment administered before surgery would offer a number of advantages compared to the traditional approach of surgery followed by adjuvant treatments. For example, in animal models, removal of the primary tumor was shown to have a permissive effect on distant micrometastases [3]; consequently, in the interval after breast surgery, micrometastases could grow to the extent that subsequent adjuvant treatments lost their efficacy. When potent chemotherapy agents such as the anthracyclines and, later, the taxanes became available, the rates of tumor regression observed in breast tumors were so impressive that NAT became synonymous with neoadjuvant chemotherapy (NAC).",
author = "Laura Martincich and Ilaria Bertotto and Filippo Montemurro",
year = "2012",
month = "1",
day = "1",
doi = "10.1007/978-88-470-2613-1_6",
language = "English",
isbn = "9788847026131",
pages = "95--108",
booktitle = "Imaging Tumor Response to Therapy",
publisher = "Springer-Verlag Italia s.r.l.",

}

TY - CHAP

T1 - Neoadjuvant therapy in breast cancer

AU - Martincich, Laura

AU - Bertotto, Ilaria

AU - Montemurro, Filippo

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Neoadjuvant therapy (NAT), often referred to as primary therapy, is a wellestablished approach in the treatment of early breast cancer [1, 2]. Historically, NAT was initially used in women with locally advanced breast cancer. In this setting it represented the only chance for a patient with an otherwise inoperable cancer of the breast to obtain a tumor regression that made surgery feasible. These experiences in locally advanced tumors suggested that the primary breast cancers regressed frequently and, sometimes, became clinically undetectable during NAT. From locally advanced tumors, NAT was then studied in women with operable breast cancers, in whom it was speculated that anticancer treatment administered before surgery would offer a number of advantages compared to the traditional approach of surgery followed by adjuvant treatments. For example, in animal models, removal of the primary tumor was shown to have a permissive effect on distant micrometastases [3]; consequently, in the interval after breast surgery, micrometastases could grow to the extent that subsequent adjuvant treatments lost their efficacy. When potent chemotherapy agents such as the anthracyclines and, later, the taxanes became available, the rates of tumor regression observed in breast tumors were so impressive that NAT became synonymous with neoadjuvant chemotherapy (NAC).

AB - Neoadjuvant therapy (NAT), often referred to as primary therapy, is a wellestablished approach in the treatment of early breast cancer [1, 2]. Historically, NAT was initially used in women with locally advanced breast cancer. In this setting it represented the only chance for a patient with an otherwise inoperable cancer of the breast to obtain a tumor regression that made surgery feasible. These experiences in locally advanced tumors suggested that the primary breast cancers regressed frequently and, sometimes, became clinically undetectable during NAT. From locally advanced tumors, NAT was then studied in women with operable breast cancers, in whom it was speculated that anticancer treatment administered before surgery would offer a number of advantages compared to the traditional approach of surgery followed by adjuvant treatments. For example, in animal models, removal of the primary tumor was shown to have a permissive effect on distant micrometastases [3]; consequently, in the interval after breast surgery, micrometastases could grow to the extent that subsequent adjuvant treatments lost their efficacy. When potent chemotherapy agents such as the anthracyclines and, later, the taxanes became available, the rates of tumor regression observed in breast tumors were so impressive that NAT became synonymous with neoadjuvant chemotherapy (NAC).

UR - http://www.scopus.com/inward/record.url?scp=84956989460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956989460&partnerID=8YFLogxK

U2 - 10.1007/978-88-470-2613-1_6

DO - 10.1007/978-88-470-2613-1_6

M3 - Chapter

SN - 9788847026131

SN - 9788847026124

SP - 95

EP - 108

BT - Imaging Tumor Response to Therapy

PB - Springer-Verlag Italia s.r.l.

ER -